IL-2: The First Effective Immunotherapy for Human Cancer

The ability of IL-2 to expand T cells with maintenance of functional activity has been translated into the first reproducible effective human cancer immunotherapies. The administration of IL-2 can lead to durable, complete, and apparently curative regressions in patients with metastatic melanoma and renal cancer. The growth of large numbers of tumor-infiltrating lymphocytes with in vitro anti-cancer activity in IL-2 has led to the development of cell transfer therapies that are highly effective in patients with melanoma. The genetic modification of T cells with genes encoding αβ TCRs or chimeric Ag receptors and the administration of these cells after expansion in IL-2 have extended effective cell transfer therapy to other cancer types.

[1]  B. Shalmon,et al.  Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies , 2013, Clinical Cancer Research.

[2]  Jimmy Lin,et al.  Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.

[3]  S. Rosenberg,et al.  Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors , 2013, Nature Reviews Clinical Oncology.

[4]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[5]  Jeffrey E. Lee,et al.  Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients , 2012, Clinical Cancer Research.

[6]  V. Sondak,et al.  Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma , 2012, Journal of immunotherapy.

[7]  S. Steinberg,et al.  Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. , 2012, Blood.

[8]  S. Rosenberg,et al.  CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma , 2012, Clinical Cancer Research.

[9]  Steven A. Rosenberg,et al.  Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know , 2011, Nature Reviews Clinical Oncology.

[10]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[11]  M. Merino,et al.  T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[14]  G. Trinchieri,et al.  Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. , 2010, Cancer research.

[15]  S. Rosenberg,et al.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[17]  S. Rosenberg,et al.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Steinberg,et al.  High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma , 2008, Cancer.

[19]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[20]  S. Rosenberg,et al.  Adoptive immunotherapy for cancer: building on success , 2006, Nature Reviews Immunology.

[21]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[22]  S. Steinberg,et al.  Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[24]  F. Marincola,et al.  A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma , 2002, Journal of immunotherapy.

[25]  F. Marincola,et al.  Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma , 2001, Journal of immunotherapy.

[26]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Steinberg,et al.  Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. , 1998, Annals of surgery.

[28]  S. Rosenberg,et al.  Trends in the safety of high dose bolus interleukin‐2 administration in patients with metastatic cancer , 1998, Cancer.

[29]  R. Wiltrout,et al.  Immune Responses To Metastases , 1996 .

[30]  R. Fisher,et al.  Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Rosenberg,et al.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.

[32]  K. Sakaguchi,et al.  Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  S. Steinberg,et al.  In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Rosenberg,et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.

[36]  S. Steinberg,et al.  Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. , 1993, Journal of the National Cancer Institute.

[37]  N. Barth,et al.  HIGH DOSE CONTINUOUS INFUSION INTERLEUKIN-2 IN 788 CANCER PATIENTS: THE NATIONAL BIOTHERAPY STUDY GROUP EXPERIENCE , 1992 .

[38]  S. Rosenberg,et al.  The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  K. Cornetta,et al.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.

[40]  M. Atkins,et al.  An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. , 1990, The New England journal of medicine.

[41]  G. Semenzato Lymphokine activated killer cells: a new approach to immunotherapy of cancer. , 1990, Leukemia.

[42]  M. Lotze,et al.  A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  S. Rosenberg,et al.  In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. , 1989, Journal of the National Cancer Institute.

[44]  S M Larson,et al.  Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[46]  W. Linehan,et al.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  S. Rosenberg,et al.  Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. , 1987, Journal of immunological methods.

[48]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[49]  S. Rosenberg,et al.  Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. , 1987, Journal of immunology.

[50]  A. Chang,et al.  High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. , 1986, JAMA.

[51]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[52]  S. Rosenberg,et al.  Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells. , 1986, Journal of immunology.

[53]  S. Rosenberg,et al.  Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. , 1986, Cancer research.

[54]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[55]  S. Rosenberg,et al.  In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. , 1985, Journal of immunology.

[56]  S. Rosenberg,et al.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2 , 1985, The Journal of experimental medicine.

[57]  S. Rosenberg,et al.  Successful therapy of hepatic metastases from several murine tumors using lymphokine-activated killer cells and recombinant interleukin-2 , 1985 .

[58]  S. Rosenberg,et al.  In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. , 1985, Journal of immunology.

[59]  M. Doyle,et al.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli. , 1984, Science.

[60]  V. Chowdhry,et al.  Purification and partial sequence analysis of human T-cell growth factor. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Jan Tavernier,et al.  Molecular cloning of human interleukin 2 cDNA and its expression in E. coli , 1983, Nucleic Acids Res..

[62]  T. Taniguchi,et al.  Structure and expression of a cloned cDNA for human interleukin-2 , 1983, Nature.

[63]  S. Rosenberg,et al.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells , 1983, The Journal of experimental medicine.

[64]  T. Eberlein,et al.  Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. , 1982, The Journal of experimental medicine.

[65]  S. Rosenberg,et al.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes , 1982, The Journal of experimental medicine.

[66]  P. Greenberg,et al.  Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes , 1981, The Journal of experimental medicine.

[67]  T. Eberlein,et al.  In vitro growth of murine T cells. VI. Accelerated skin graft rejection caused by adoptively transferred cells expanded in T cell growth factor. , 1981, Journal of immunology.

[68]  S. Rosenberg,et al.  In vitro growth of cytotoxic human lymphocytes. III. The preparation of lectin-free T cell growth factor (TCGF) and an analysis of its activity. , 1981, Journal of immunology.

[69]  P. Greenberg,et al.  Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with Interleukin 2. , 1981, Journal of immunology.

[70]  D. Mathisen,et al.  The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. , 1980, Journal of immunology.

[71]  S. Rosenberg,et al.  In vitro growth of murine T cells. IV. Use of T-cell growth factor to clone lymphoid cells. , 1980, Cellular immunology.

[72]  S. Rosenberg,et al.  In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. , 1980, Journal of immunology.

[73]  S. Rosenberg,et al.  In vitro growth of cytotoxic human lymphocytes. II. Use of T cell growth factor (TCGF) to clone human T cells. , 1980, Journal of immunology.

[74]  D. Mathisen,et al.  Comparison of in vivo cell distribution following either intraperitoneal or intravenous injection of lymphoid cells. , 1980, Transplantation.

[75]  S. Rosenberg,et al.  In vitro growth of murine T cells. III. Method for separation of T cell growth factor (TCGF) from concanavalin A and biological activity of the resulting TCGF. , 1980, Journal of immunological methods.

[76]  H. Wigzell,et al.  Long term growth in vitro of human T cell blasts with maintenance of specificity and function. , 1979, Journal of immunology.

[77]  K. Smith,et al.  Monoclonal cytolytic T-cell lines , 1979, The Journal of experimental medicine.

[78]  S. Rosenberg,et al.  In vitro growth of murine T cells. II. Growth of in vitro sensitized cells cytotoxic for alloantigens. , 1978, Journal of immunology.

[79]  S. Rosenberg,et al.  In vitro growth of murine T cells. I. Production of factors necessary for T cell growth. , 1978, Journal of immunology.

[80]  S. Rosenberg,et al.  In vitro growth of cytotoxic human lymphocytes. I. Growth of cells sensitized in vitro to alloantigens. , 1978, Journal of immunology.

[81]  K. Smith,et al.  Long-term culture of human antigen-specific cytotoxic T-cell lines , 1978, The Journal of experimental medicine.

[82]  Kendall A. Smith,et al.  Long term culture of tumour-specific cytotoxic T cells , 1977, Nature.

[83]  S. Rosenberg,et al.  Passive immunotherapy of cancer in animals and man. , 1977, Advances in cancer research.

[84]  R. Gallo,et al.  Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.

[85]  N. Mitchison,et al.  STUDIES ON THE IMMUNOLOGICAL RESPONSE TO FOREIGN TUMOR TRANSPLANTS IN THE MOUSE , 1955, The Journal of experimental medicine.